PKM and non-small cell lung carcinoma: Metformin treatment decreased the expression of pyruvate kinase muscle isozyme M2 (PKM2), the enzyme that catalyses the final step in glycolysis, and consequently inhibited partially glucose metabolism and reduced ATP levels in carboplatin-resistant NSCLC cells [210].